Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Planning Grants - PA: Community-based Primary Healthcare

University of British Columbia

$14,322.00

Feasibility of a randomized controlled trial of ketotifen for lateral epicondylalgia

EF 2011-12

Résumé
Lateral epicondylitis (LE) is common tendinopathy seen in workers engaged in repetitive manual or gripping activities. While its prevalence in the general population is approximately 3%, in certain industries the prevalence is much higher (e.g. 15% in fish-processing workers). It is more common in individuals 45-54 years of age, and equally common in women and men, according to a recent study. The major risk factors for LE include diabetes, smoking, and forceful or repetitive gripping activities. Although LE appears to be a relatively benign disorder involving injury to the common extensor tendons, the annual cost to WorksafeBC averaged 10 million per year from 2005-2010. Recent systematic reviews have identified several treatments with partial effectiveness for LE. Corticosteroid injections lead to improvements in pain and pain-free grip strength in the short term (3 months), but in fact lead to worse clinical status on average in the long run (12 months) due to a higher rate of symptom recurrence. Comprehensive physiotherapy management leads to improved outcomes at 6 weeks, but no difference in longer term outcomes (12 months). Recent advances in our understanding of tendinopathy by Scott, Hart and others have identified the potential for a new category of drugs - mast cell inhibitors - to meaningfully impact the process of tendon repair. One such drug, ketotifen, is already in use clinically to treat a variety of conditions including asthma, conjunctivitis, post-operative gastrointestinal transit, and mastocytosis. The objective of the current Planning Grant request is to assemble a working international team which spans biological, clinical, occupational health, and epidemiological sciences. The primary outcomes will be (1) regular team meetings, (2) an international symposium, and (3) the development of an RCT protocol and (4) potential application of a Team Grant.
Programme
Planning Grants - PA: Community-based Primary Healthcare
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
236615
Name
Scott Alexander
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Planning Grants
Projecttitle
Feasibility of a randomized controlled trial of ketotifen for lateral epicondylalgia
Programtype2
Miscellaneous Programs
Orgnameinp2
University of British Columbia
Cihramount2
$14,322
Cihrequipment2
$0
Programname2
Planning Grants - PA: Community-based Primary Healthcare
Keyworddelim
Lateral Epicondylalgia; Occupational Injuries
Abstract
Lateral epicondylitis (LE) is common tendinopathy seen in workers engaged in repetitive manual or gripping activities. While its prevalence in the general population is approximately 3%, in certain industries the prevalence is much higher (e.g. 15% in fish-processing workers). It is more common in individuals 45-54 years of age, and equally common in women and men, according to a recent study. The major risk factors for LE include diabetes, smoking, and forceful or repetitive gripping activities. Although LE appears to be a relatively benign disorder involving injury to the common extensor tendons, the annual cost to WorksafeBC averaged 10 million per year from 2005-2010. Recent systematic reviews have identified several treatments with partial effectiveness for LE. Corticosteroid injections lead to improvements in pain and pain-free grip strength in the short term (3 months), but in fact lead to worse clinical status on average in the long run (12 months) due to a higher rate of symptom recurrence. Comprehensive physiotherapy management leads to improved outcomes at 6 weeks, but no difference in longer term outcomes (12 months). Recent advances in our understanding of tendinopathy by Scott, Hart and others have identified the potential for a new category of drugs - mast cell inhibitors - to meaningfully impact the process of tendon repair. One such drug, ketotifen, is already in use clinically to treat a variety of conditions including asthma, conjunctivitis, post-operative gastrointestinal transit, and mastocytosis. The objective of the current Planning Grant request is to assemble a working international team which spans biological, clinical, occupational health, and epidemiological sciences. The primary outcomes will be (1) regular team meetings, (2) an international symposium, and (3) the development of an RCT protocol and (4) potential application of a Team Grant.
Competitiondate
201106
Approvedterm2
1 yr 0 mth
Pinamesdelim
Scott, Alexander
Approvedterm
1 an 0 mois
Cihrcontribution2
Inst of Musculoskel Hlth &Arth~ $14,322~ $0~